secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001493152-22-031246
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs Q3 net revenue $24.2M (+155% YoY), net income $1.0M vs loss, adj. EBITDA $6.3M record
--------------------------------------------------------------------------------

- Q3 2022 net revenue $24.2M, up 155% from $9.5M in Q3 2021; net income $1.0M ($0.06 EPS) vs net loss $4.0M ($0.26 loss).
- Adjusted EBITDA $6.3M (record for Q3) versus adjusted EBITDA loss of $1.3M in the prior-year quarter.
- Cash, cash equivalents & restricted cash $22.8M at Sep 30, 2022 vs $8.7M at Dec 31, 2021; working capital $53.6M.
- Signed MOU with G42 Healthcare for genomic sequencing/AI; entered two-year collaborative agreement with Dana-Farber for Linebacker-1 cancer co-therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315222031246/0001493152-22-031246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315222031246/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer